Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma

Evofosfamide (Evo or TH302) is a hypoxia-activated prodrug which is reduced leading to the release of alkylating agent bromo-isophosphoramide mustard, which has shown safety and signals of efficacy in a prior phase 1 study in recurrent glioblastoma. We performed a dual center single-arm Phase II stu...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Sci Rep
Main Authors: Brenner, Andrew J., Floyd, John, Fichtel, Lisa, Michalek, Joel, Kanakia, Kunal P., Huang, Shiliang, Reardon, David, Wen, Patrick Y., Lee, Eudocia Quant
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2021
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841164/
https://ncbi.nlm.nih.gov/pubmed/33504881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-81841-0
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker